Hereditary hemochromatosis: Progress and perspectives

Reviews in Clinical and Experimental Hematology

Volumn 4, Issue 4, 2000, Pages 302-321

  Camaschella, Clara ^a   De Gobbi, Marco ^a   Roetto, Antonella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFERRIN RECEPTOR;

AUTOSOMAL RECESSIVE DISORDER; CHROMOSOME 1Q; CHROMOSOME 7Q; EARLY DIAGNOSIS; GENE MUTATION; GENETIC LINKAGE; HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; LIFE EXPECTANCY; LIVER BIOPSY; PHLEBOTOMY; RECEPTOR DOWN REGULATION; REVIEW; SYMPTOMATOLOGY;

EID: 0034583879     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2000.00022.x     Document Type: Review

References (123)

1. Primary iron overload
2. Association of HLA A3 and HLA B14 antigens with idiopathic hemochromatosis
3. Idiopathic hemochromatosis: Demonstration of recessive transmission and early detection by family HLA typing
4. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
5. Beta2 microglobulin knock out mice develop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism
6. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor
7. Functions of nonclassical MHC and non-MHC-encoded class I molecules
8. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis
9. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding
10. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum
11. Crystal structure of the hereditary hemochromatosis protein HFE complexed with transferrin receptor
12. Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: Implications for cellular iron homeostasis
13. HFE knock out produces mouse model of hereditary hemochromatosis
14. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression
15. A simple genetic test identifies 90% of UK patients with haemochromatosis
16. Hemochromatosis in Ireland and HFE
17. HFE mutations in patients with hereditary hemochromatosis in Sweden
18. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany
19. HFE mutations analysis in 711 hemochromatosis probands: Evidence for S65C implication in mild form of haemochromatosis
20. Phenotypic expression of HFE mutations: A French study of 1110 unrelated iron-overloaded patients and relatives
21. Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic haemochromatosis
22. Mutation analysis in hereditary hemochromatosis
23. Correlation between genotype and phenotype in hereditary hemochromatosis: Analysis of 61 cases
24. Genetic and clinical description of hemochromatosis probands and heterozygotes: Evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis
25. Mutation analysis of HLA-H gene in Italian hemochromatosis patients
26. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients
27. Heterogeneity of hemochromatosis in Italy
28. Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls
29. Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity
30. Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria
31. Mutation analysis in the HFE gene in patients with hereditary hemochromatosis in Saguenay-Lac-Saint Jean (Quebec, Canada)
32. Global prevalence of putative hemochromatosis mutations
33. Celtic origin of the C282Y mutation of hemochromatosis
34. The significance of the 187G (H63D) mutation in hemochromatosis
35. Molecular medicine and hemochromatosis: At the crossroads
36. Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands
37. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote
38. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis
39. Evolving expression of hereditary hemochromatosis
40. Diagnosis of hemochromatosis
41. Hereditary hemochromatosis: Recent advances in molecular genetics and clinical management
42. The relationship between iron overload, clinical symptoms and age in 410 patients with genetic hemochromatosis
43. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation
44. A population-based study of the clinical expression of the hemochromatosis gene
45. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis
46. Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of histological hepatic iron index: A study of 192 cases
47. Non invasive prediction of fibrosis in C282Y homozygous hemochromatosis
48. Magnetic susceptibility measurement of human iron stores
49. Non invasive methods for early detection of hereditary hemochromatosis
50. Clinical characteristics of hereditary hemochromatosis in patients who lack the C282Y mutation
51. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis
52. Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people
53. Hereditary hemochromatosis in children, adolescents and young adults
54. Primary hemochromatosis in children; report of three newly diagnosed cases and review of the pediatric literature
55. Juvenile idiopathic haemochromatosis: A life-threatening disorder presenting as hypogonadotropic hypogonadism
56. Juvenile hemochromatosis
57. Heart transplantation in a case of juvenile hereditary haemochromatosis followed up by MRI and endomyocardial biopsies
58. Hereditary juvenile haemochromatosis: A genetically heterogeneous life-threatening iron storage disease
59. A case of non-HFE juvenile hemochromatosis presenting with adrenocortical insufficiency
60. Successful pregnancy following gonadotropin therapy in a young female with juvenile idiopathic hemochromatosis and secondary hypogonadotropic hypogonadism
61. Juvenile hemochromatosis associated with β-thalassemia treated by phlebotomy and recombinant human erythropoietin
62. Juvenile and adult hemochromatosis are distinct genetic disorders
63. The juvenile hemochromatosis locus maps to chromosome 1q
64. Clinical and molecular aspects of juvenile hemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada)
65. Juvenile genetic hemochromatosis is clinically and genetically distinct from the classical HLA-related disorder
66. High-resolution YAC fragmentation map of 1q21
67. Exclusion of ZIRTL as candidate gene of juvenile hemochromatosis and refinement of the critical interval on 1q21
68. Inherited HFE-unrelated hemochromatosis in Italian families
69. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene
70. The gene encoding transferrin receptor 2 is mutated in a new type of hemochromatosis mapping to 7q22
71. Molecular cloning of transferrin receptor 2
72. Transferrin receptor 2-α supports cell growth both in iron chelated cultured cells and in vitro
73. Transferrin receptor is necessary for development of erythrocytes and the nervous system
74. Transferrin receptor 2: Continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis
75. Diagnosis and management of haemochromatosis since the discovery of the HFE gene: An European experience
76. A new syndrome of liver iron overload with normal transferrin saturation
77. Insulin resistance-associated hepatic iron overload
78. Insulin resistance, iron and the liver
79. Hyperferritinemia-cataract syndrome: Three recurrent mutations in the IRE of L-ferritin in Italian families
80. Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome
81. Classification and diagnosis of iron overload
82. Management of hemochromatosis
83. Survival and cause of death in cirrhotic and non cirrhotic patients with primary hemochromatosis
84. Longterm survival in patients with hereditary hemochromatosis
85. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis
86. Recovery of pancreatic β-cell function in hemochromatosis: Combined treatment with recombinant human erythropoietin and phlebotomy
87. Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy
88. Genes that modify the hemochromatosis phenotype in mice
89. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene
90. Disorders of iron metabolism
91. Interaction between a gene and dietary iron content
92. Is there a link between African iron overload and the described mutations of the hereditary hemochromatosis gene?
93. Primary iron overload in African Americans
94. Mutation analysis of the HFE gene associated with hereditary hemochromatosis in African Americans
95. Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism
96. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans
97. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux
98. Neonatal hemochromatosis
99. The genetic basis of neonatal haemochromatosis
100. Iron overload, public health and genetics: Evaluating the evidence for hemochromatosis screening
101. Population screening for haemochromatosis
102. Population screening in hereditary hemochromatosis
103. EASL International Consensus Conference on Haemochromatosis
104. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors
105. Population screening for hemochromatosis: A comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors
106. Strategies to increase detection of hemochromatosis
107. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in hemochromatosis
108. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results
109. A pilot C282Y hemochromatosis screening in Italian newborns by Taqman™ technology
110. Transferrin saturation phenotype and HFE genotype screening for hemochromatosis and primary iron overload: Predictions from a model based on national, racial, and ethnic group composition in central Alabama
111. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda
112. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda
113. Porphyria cutanea tarda, hepatitis C and HFE gene mutations in North America
114. Four new mutations in the erythroid-specific 5-aminolevulate-synthase (ALAS2) gene causing X-linked sideroblastic anemia: Increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis
115. Aetiology of severe iron overload in a family with hereditary haemolytic anemia
116. Determination of iron status and bilirubin levels in dyserythropoietic anemia type I
117. Haemochromatosis in patients with β-thalassemia trait
118. The influence of haemochromatosis mutations on iron overload of thalassemia major
119. The haemochromatosis mutations do not modify the clinical picture of thalassemia major in patients regularly transfused and chelated
120. - T cells
121. γδ intraepithelial lymphocytes drive tumor necrosis factor-α responsiveness to intestinal iron challenge: Relevance to hemochromatosis
122. A novel mutation of HFE explains the phenotype of hereditary hemochromatosis in a C282Y carrier
123. A single nucleotide deletion in the putative haemochromatosis gene in a patient who is negative for both the C282Y and H63D mutations